A Multicenter, Double-blind, Randomized, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of CJ-12420 in Patients With Non-erosive Reflux Disease
Phase of Trial: Phase III
Latest Information Update: 02 Jan 2017
At a glance
- Drugs Tegoprazan (Primary)
- Indications Gastro-oesophageal reflux
- Focus Therapeutic Use
- Sponsors CJ HealthCare
- 28 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017.
- 28 Dec 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Jun 2017.
- 20 Apr 2016 Status changed from not yet recruiting to recruiting.